The company is still moving forward... 10/5/20.
Post# of 9144
(Total Views: 584)
Posted On: 07/07/2021 7:16:51 AM
The company is still moving forward...
10/5/20..."NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system."
Then we get the setback from the whistle blower issue. Once that ended we get
03/10/21..."The Company is pleased to announce the achievement of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
Those are:
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
More good news...
04/13/21..."We are pleased to announce receipt of Notice Of Allowance for a second Rapid Viral Assay Patent from the US Patent Office. The notice is for a Continuation-In-Part filed on November 21, 2020 for the Parent Patent issued November 24, 2020. It involves further protection for 20 approved claims relating to methods and a range of additional viruses for which rapid and accurate detection is vital. These include, for example, Middle East Respiratory Syndrome (MERS).
Our strategy of filing additional Continuation-In-Part patent applications for the ongoing research for SARS2/COVID19 Rapid Viral Assay development taking place between NanoLogix and several critical partners is projected to continue. These entities include a diagnostic company, a research team at a significant university, and a developing collaboration with a highly regarded research organization."
I see light at the end of the tunnel, don't know about anyone else.
Does anyone know what the status of this announcement is?
10/14/20..."NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics."
10/5/20..."NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system."
Then we get the setback from the whistle blower issue. Once that ended we get
03/10/21..."The Company is pleased to announce the achievement of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
Those are:
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
More good news...
04/13/21..."We are pleased to announce receipt of Notice Of Allowance for a second Rapid Viral Assay Patent from the US Patent Office. The notice is for a Continuation-In-Part filed on November 21, 2020 for the Parent Patent issued November 24, 2020. It involves further protection for 20 approved claims relating to methods and a range of additional viruses for which rapid and accurate detection is vital. These include, for example, Middle East Respiratory Syndrome (MERS).
Our strategy of filing additional Continuation-In-Part patent applications for the ongoing research for SARS2/COVID19 Rapid Viral Assay development taking place between NanoLogix and several critical partners is projected to continue. These entities include a diagnostic company, a research team at a significant university, and a developing collaboration with a highly regarded research organization."
I see light at the end of the tunnel, don't know about anyone else.
Does anyone know what the status of this announcement is?
10/14/20..."NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics."
(7)
(0)